
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7883013/publications.pdf Version: 2024-02-01



Μλιίρ Μλαιλνι

#	Article	IF	CITATIONS
1	Effect of bromhexine in hospitalized patients with COVID-19. Journal of Investigative Medicine, 2023, 71, 691-699.	0.7	22
2	Multimorbidity among persons living with human immunodeficiency virus in a moroccan referral hospital. International Journal of Mycobacteriology, 2022, 11, 16.	0.3	1
3	Pulmonary manifestations in a cohort of patients with inborn errors of immunity: an 8-year follow-up study. Allergologia Et Immunopathologia, 2022, 50, 80-84.	1.0	3
4	The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review. Current Therapeutic Research, 2022, 96, 100658.	0.5	12
5	Myocarditis following rAd26 and rAd5 vectorâ€based COVIDâ€19 vaccine: case report. ESC Heart Failure, 2022, 9, 1483-1486.	1.4	19
6	Transmission electron microscopy study of suspected primary ciliary dyskinesia patients. Scientific Reports, 2022, 12, 2375.	1.6	3
7	Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series. Annals of Clinical Microbiology and Antimicrobials, 2022, 21, 8.	1.7	7
8	National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19. Iranian Journal of Pharmaceutical Research, 2022, 21, .	0.3	3
9	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. Immunological Investigations, 2021, 50, 884-890.	1.0	18
10	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. International Immunopharmacology, 2021, 90, 107205.	1.7	64
11	Tuberculosis and COVID-19 co-infection: A case series from Iran. International Journal of Mycobacteriology, 2021, 9, 3.	0.3	0
12	Value of serologic assay in diagnosis of COVID-19 among patients with negative molecular assay. International Journal of Mycobacteriology, 2021, 9, 62.	0.3	0
13	Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. International Immunopharmacology, 2021, 92, 107329.	1.7	15
14	No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. European Journal of Pharmacology, 2021, 897, 173947.	1.7	66
15	Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 592727.	2.2	53
16	Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-6.	0.7	10
17	Serum cytokine levels of COVID-19 patients after 7Âdays of treatment with Favipiravir or Kaletra. International Immunopharmacology, 2021, 93, 107407.	1.7	16
18	Differential Gene Expression of ASUN, NEMF, PTPRC and DHX29: Candidate Biomarkers for the Diagnosis of Active and Latent Tuberculosis. Infectious Disorders - Drug Targets, 2021, 21, 268-273.	0.4	3

#	Article	IF	CITATIONS
19	Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. Human Antibodies, 2021, 29, 109-113.	0.6	7
20	Not all that is miliary is tuberculosis: Metastatic medullary thyroid carcinoma mimicking miliary tuberculosis. Clinical Case Reports (discontinued), 2021, 9, e04231.	0.2	0
21	Disseminated Mycobacterium simiae Infection in a Patient with Complete IL-12p40 Deficiency. Iranian Journal of Allergy, Asthma and Immunology, 2021, 20, 376-381.	0.3	2
22	Immune cell profiling and antibody responses in patients with COVID-19. BMC Infectious Diseases, 2021, 21, 646.	1.3	17
23	Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature. Pediatric Rheumatology, 2021, 19, 121.	0.9	8
24	The relationship between serum 25-hydroxyvitamin D levels and the severity of COVID-19 disease and its mortality. Scientific Reports, 2021, 11, 17594.	1.6	20
25	Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. International Archives of Allergy and Immunology, 2021, 182, 254-262.	0.9	36
26	Potential diagnostic value of pleural fluid cytokines levels for tuberculous pleural effusion. Scientific Reports, 2021, 11, 660.	1.6	12
27	Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology, 2021, 27, 486-492.	1.0	33
28	T Helper Cell Subsets in the Pleural Fluid of Tuberculous Patients Differentiate Patients With Non-Tuberculous Pleural Effusions. Frontiers in Immunology, 2021, 12, 780453.	2.2	3
29	Diagnosis of COVID-19 by Serology in Admitted Patients with Negative RT-PCR Assay. Iranian Journal of Allergy, Asthma and Immunology, 2021, 20, 394-401.	0.3	0
30	The Effect of acetyl-L-carnitine, Alpha-lipoic Acid, and Coenzyme Q10 Combination in Preventing Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized, Double-blind, Placebo-controlled Clinical Trial Iranian Journal of Pharmaceutical Research, 2021, 20, 431-440.	0.3	1
31	Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form Iranian Journal of Pharmaceutical Research, 2021, 20, 1-8.	0.3	10
32	Bronchial Angioembolization for Management of Hemoptysis Due to Pulmonary Tuberculosis Tanaffos, 2021, 20, 134-139.	0.5	0
33	Descriptive Analysis of COVID-19 among Health Care Workers in a Tertiary Center in Iran Tanaffos, 2021, 20, 246-252.	0.5	0
34	NRITLD Protocol for the Management of Outpatient Cases of COVID-19 Tanaffos, 2021, 20, 192-196.	0.5	0
35	Delay in the Diagnosis of APECED: A Case Report and Review of Literature from Iran. Immunological Investigations, 2020, 49, 299-306.	1.0	3
36	Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients. Pathology Research and Practice, 2020, 216, 153228.	1.0	30

#	Article	lF	CITATIONS
37	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International Immunopharmacology, 2020, 88, 106869.	1.7	40
38	Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillus nidulans complex and Aspergillus terreus complex isolated from clinical specimens. Journal De Mycologie Medicale, 2020, 30, 101004.	0.7	4
39	Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. International Immunopharmacology, 2020, 85, 106688.	1.7	67
40	Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical and Genetic Features of 32 Iranian Patients. Journal of Clinical Immunology, 2020, 40, 872-882.	2.0	22
41	Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. Journal of Clinical Immunology, 2020, 40, 974-976.	2.0	59
42	Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency. New England Journal of Medicine, 2020, 382, 437-445.	13.9	38
43	A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. Iranian Journal of Pharmaceutical Research, 2020, 19, 31-36.	0.3	30
44	Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. Iranian Journal of Pharmaceutical Research, 2020, 19, 1-2.	0.3	11
45	Incidence of Phlebitis Associated With Peripheral Venous Catheter of Patients With COVID-19. Hospital Practices and Research, 2020, 5, 79-80.	0.1	0
46	Evaluation of Th9 and Th22 cells within pleural effusions of tuberculosis and non-tuberculosis patients. , 2020, , .		0
47	Evaluation of treatment response in active tuberculosis using QuantiFERON-TB Gold Plus. European Cytokine Network, 2020, 31, 129-133.	1.1	1
48	Clinical outcomes and complications ofÂfiberoptic bronchoscopy in HIV-infected patients. HIV and AIDS Review, 2020, 19, 172-179.	0.1	0
49	The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. Journal of Research in Medical Sciences, 2020, 25, 24.	0.4	3
50	A Novel Coronavirus Disease (COVID-19): a Review of Host Cell Signaling Pathways. Tanaffos, 2020, 19, 108-111.	0.5	4
51	Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. Tanaffos, 2020, 19, 122-128.	0.5	3
52	Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19. Tanaffos, 2020, 19, 85-88.	0.5	6
53	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. Tanaffos, 2020, 19, 91-99.	0.5	10
54	Differential genes expression analysis of invasive aspergillosis: a bioinformatics study based on mRNA/microRNA. Molecular Biology Research Communications, 2020, 9, 173-180.	0.2	0

#	Article	IF	CITATIONS
55	Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients. Tanaffos, 2020, 19, 291-299.	0.5	1
56	Trisomy 21 as a Risk Factor for Severe Illness in COVID-19: Report of two Cases. Tanaffos, 2020, 19, 413-417.	0.5	1
57	Evaluation of inflammatory mediators of pleural effusion in tuberculosis and non-tuberculosis patients. , 2020, , .		0
58	The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. Journal of Research in Medical Sciences, 2020, 25, 24.	0.4	7
59	Diagnostic accuracy of interferon (IFN)-γ inducible protein 10 (IP-10) as a biomarker for the discrimination of active and latent tuberculosis. Molecular Biology Reports, 2019, 46, 6263-6269.	1.0	12
60	Characterization of Clostridioides difficile isolates recovered from hospitalized patients and the hospitals environment and air: A multicenter study. Anaerobe, 2019, 59, 154-158.	1.0	7
61	Diagnostic Accuracy of Monocyte Chemotactic Protein (MCP)-2 as Biomarker in Response to PE35/PPE68 Proteins: A Promising Diagnostic Method for the Discrimination of Active and Latent Tuberculosis. Protein and Peptide Letters, 2019, 26, 281-286.	0.4	7
62	Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 45-49.	0.1	13
63	Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 138-142.	0.6	10
64	Etiology of Respiratory Complications among Iranian HIV Infected Patients. Tanaffos, 2019, 18, 96-103.	0.5	0
65	Enterovirus-Human Rhinovirus as a Leading Cause of ARDS in a Liver Transplant Recipient. Tanaffos, 2019, 18, 169-172.	0.5	0
66	Diagnosing active and latent tuberculosis among Iranian HIVâ€infected patients. Clinical Respiratory Journal, 2018, 12, 62-67.	0.6	2
67	Risk factors for mortality among tuberculosis patients co-infected with HIV. Infectious Diseases, 2018, 50, 399-402.	1.4	Ο
68	An adult autosomal recessive chronic granulomatous disease patient with pulmonary Aspergillus terreus infection. BMC Infectious Diseases, 2018, 18, 552.	1.3	5
69	Pathogenicity locus determinants and toxinotyping of Clostridioides difficile isolates recovered from Iranian patients. New Microbes and New Infections, 2018, 25, 52-57.	0.8	4
70	Implementing tuberculosis close-contact investigation in a Tertiary Hospital in Iran. International Journal of Preventive Medicine, 2018, 9, 48.	0.2	4
71	Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital. Tanaffos, 2018, 17, 183-187.	0.5	0
72	Caspofungin as Salvage Therapy for Pneumocystis Pneumonia in a Heart Transplant Recipient. Tanaffos, 2018, 17, 203-206.	0.5	2

#	Article	IF	CITATIONS
73	miR-1224 Expression Is Increased in Human Macrophages after Infection with Bacillus Calmette-Guérin (BCG). Iranian Journal of Allergy, Asthma and Immunology, 2018, 17, 250-257.	0.3	6
74	Recurrent Drug-Induced Hepatitis in Tuberculosis—Comparison of Two Drug Regimens. American Journal of Therapeutics, 2017, 24, e144-e149.	0.5	2
75	Paecilomyces formosus Infection in an Adult Patient with Undiagnosed Chronic Granulomatous Disease. Journal of Clinical Immunology, 2017, 37, 342-346.	2.0	13
76	Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. Journal of Global Antimicrobial Resistance, 2017, 11, 116-119.	0.9	1
77	Pulmonary Actinomycosis in a Patient with AIDS/HCV. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OD15-OD17.	0.8	6
78	A Potentially Fatal Error in Diagnosis of a Pulmonary Hydatid Cyst. Archives of Clinical Infectious Diseases, 2017, 13, .	0.1	0
79	Antifungal Resistant Gastrointestinal Basidiobolomycosis Without Eosinophilia: A Case Report. Archives of Clinical Infectious Diseases, 2017, 12, .	0.1	Ο
80	Acute Epstein - Barr virus hepatitis without mononucleosis syndrome: a case report. Gastroenterology and Hepatology From Bed To Bench, 2017, 10, 147-149.	0.6	5
81	Yield of mycobacteriological study in diagnosis of pleural tuberculosis among Human immune deficiency virus-infected patients. International Journal of Mycobacteriology, 2016, 5, S112-S113.	0.3	3
82	Usefulness of pulmonary artery diameter in diagnosing pulmonary hypertension in patients admitted to tuberculosis intensive care unit. International Journal of Mycobacteriology, 2016, 5, S56.	0.3	1
83	Investigation of urine lipoarabinomannan in human immunodeficiency virus patients with or without coinfection with Tuberculosis in Iran. International Journal of Mycobacteriology, 2016, 5, S186-S187.	0.3	3
84	HIV and tuberculosis trends and survival of coinfection in a referral center in Tehran: A 12-year study. International Journal of Mycobacteriology, 2016, 5, S16-S17.	0.3	4
85	Improving T-cell assays for diagnosis of latent TB infection: Confirmation of the potential role of testing Interleukin-2 release in Iranian patients. Allergologia Et Immunopathologia, 2016, 44, 314-321.	1.0	10
86	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. Journal of Global Antimicrobial Resistance, 2016, 4, 1-4.	0.9	17
87	Impact of HIV infection on tuberculous pleural effusion. International Journal of STD and AIDS, 2016, 27, 363-369.	0.5	14
88	Botryotrichum infection in an adult patient with undiagnosed chronic granulomatous disease. , 2016, , .		0
89	Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 2016, 15, 247-52.	0.3	21
90	H1N1 Influenza Patient Saved by Extracorporeal Membrane Oxygenation: First Report from Iran. The Journal of Tehran Heart Center, 2016, 11, 153-156.	0.3	2

#	Article	IF	CITATIONS
91	Tuberculosis in Solid Organ Transplantation. Tanaffos, 2016, 15, 124-127.	0.5	4
92	Screening for diabetes mellitus in tuberculosis patients in a referral center in Iran. Infectious Diseases, 2015, 47, 472-476.	1.4	6
93	Detection of latent and active tuberculosis among HIV-positive patients at the North of Tehran. International Journal of Mycobacteriology, 2015, 4, 64.	0.3	Ο
94	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. International Journal of Mycobacteriology, 2015, 4, 128.	0.3	1
95	Outcome of drug-resistant tuberculosis treatment among HIV-positive patients at the tertiary center in Tehran. International Journal of Mycobacteriology, 2015, 4, 115.	0.3	Ο
96	Radiologic manifestations of pulmonary tuberculosis in patients of intensive care units. International Journal of Mycobacteriology, 2015, 4, 233-238.	0.3	11
97	Novel T-Cell Assays for the Discrimination of Active and Latent Tuberculosis Infection: The Diagnostic Value of PPE Family. Molecular Diagnosis and Therapy, 2015, 19, 309-316.	1.6	18
98	Discriminating between latent and active tuberculosis: The role of interleukin-2 as biomarker. Journal of Infection, 2015, 70, 429-431.	1.7	16
99	Disseminated Kaposi′s sarcoma with the involvement of penis in the setting of Hiv infection. Indian Journal of Dermatology, 2015, 60, 104.	0.1	5
100	Mycobacterial infection and the impact of rifabutin treatment in organ transplant recipients: A single-center study. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, 26, 6.	0.4	11
101	Health Care Associated Middle East Respiratory Syndrome (MERS): A Case from Iran. Tanaffos, 2015, 14, 262-7.	0.5	8
102	Changes in glycosylated haemoglobin and treatment outcomes in patients with tuberculosis in Iran: a cohort study. Journal of Diabetes and Metabolic Disorders, 2014, 13, 123.	0.8	33
103	Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient. Avicenna Journal of Medicine, 2014, 4, 17.	0.3	5
104	Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. Brazilian Journal of Infectious Diseases, 2014, 18, 487-490.	0.3	9
105	Impact of chronic renal failure on anti-tuberculosis treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2014, 18, 352-356.	0.6	21
106	Diagnosis of Latent Tuberculosis Infection Among Immunodeficient Individuals: Review of Concordance Between Interferon-Î ³ Release Assays and the Tuberculin Skin Test. British Journal of Biomedical Science, 2014, 71, 115-124.	1.2	30
107	Performance of QuantiFERON TB Gold test in detecting latent tuberculosis infection in brain-dead organ donors in Iran: A brief report. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2014, 25, 1240.	0.4	9
108	Multidrug-resistant tubercular appendicitis: Report of a case. International Journal of Mycobacteriology, 2013, 2, 227-229.	0.3	1

#	Article	IF	CITATIONS
109	Diabetes mellitus and tuberculosis facts and controversies. Journal of Diabetes and Metabolic Disorders, 2013, 12, 58.	0.8	90
110	807. Critical Care Medicine, 2013, 41, A201.	0.4	0
111	Cutaneous Alternariosis With Trichosporon Infection in a Heart Transplant Recipient: A Case Report. Experimental and Clinical Transplantation, 2013, 11, 464-466.	0.2	3
112	Management of MDR-TB: Review of Iran's Experience. Tanaffos, 2013, 12, 6-15.	0.5	0
113	A 60 year-old man with AIDS and pneumonia. Tanaffos, 2013, 12, 61-2.	0.5	0
114	A Case of Chronic Granulomatous Disease with a Necrotic Mass in the Bronchus: A Case Report and a Review of Literature. Case Reports in Pulmonology, 2012, 2012, 1-4.	0.2	2
115	Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. International Journal of STD and AIDS, 2012, 23, e1-e4.	0.5	35
116	Value of third sputum smear for detection of pulmonary tuberculosis in HIV infected patients. Gastroenterology Insights, 2012, 4, 35.	0.7	1
117	Treatment outcome and mortality: Their predictors among HIV/TB co-infected patients from Iran. International Journal of Mycobacteriology, 2012, 1, 82-86.	0.3	7
118	Diagnostic yield of post-bronchoscopy sputum smear in pulmonary tuberculosis. Scandinavian Journal of Infectious Diseases, 2012, 44, 369-373.	1.5	16
119	Pulmonary disease caused by Mycobacterium simiae in Iran's national referral center for tuberculosis. Journal of Infection in Developing Countries, 2012, 6, 23-28.	0.5	39
120	Clinical and radiological deterioration due to Mycobacterium szulgai in an asthmatic patient. Journal of Infection in Developing Countries, 2012, 6, 89-91.	0.5	2
121	Incidence of Thromboembolism in Hospitalized Patients With Tuberculosis and Associated Risk Factors. Archives of Clinical Infectious Diseases, 2012, 7, .	0.1	4
122	Comparison of Serum and Bronchoalveolar Lavage Galactomannan in Diagnosing Invasive Aspergillosis in Solid-Organ Transplant Recipients. Experimental and Clinical Transplantation, 2012, 10, 278-281.	0.2	29
123	Microbial Pattern of BronchoAlveolar Lavage in Brain Dead Donors. Transplantation Proceedings, 2011, 43, 422-423.	0.3	4
124	Revised Category II Regimen as an Alternative Strategy for Retreatment of Category I Regimen Failure and Irregular Treatment Cases. American Journal of Therapeutics, 2011, 18, 343-349.	0.5	17
125	Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran. American Journal of Therapeutics, 2011, 18, e29-e34.	0.5	51
126	Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy [Short communication]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 547-550.	0.6	30

#	Article	IF	CITATIONS
127	Lethal Tuberculosis in a Previously Healthy Adult with IL-12 Receptor Deficiency. Journal of Clinical Immunology, 2011, 31, 537-539.	2.0	49
128	Tuberculosis-Associated Secondary Pneumothorax: A Retrospective Study of 53 Patients. Respiratory Care, 2011, 56, 298-302.	0.8	28
129	Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. Annals of Thoracic Medicine, 2011, 6, 91.	0.7	25
130	Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, Iran. Tanaffos, 2011, 10, 8-11.	0.5	6
131	Improving the Practice of Nutrition Therapy in the NRITLD Critically Ill Patients: An International Quality Improvement Project. Tanaffos, 2011, 10, 31-7.	0.5	8
132	Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. American Journal of Therapeutics, 2010, 17, 17-22.	0.5	43
133	A Young Woman with Diffuse Skin Lesions. Clinical Infectious Diseases, 2010, 51, 195-196.	2.9	0
134	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. Microbial Drug Resistance, 2010, 16, 81-86.	0.9	22
135	Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. Brazilian Journal of Infectious Diseases, 2010, 14, 639-640.	0.3	8
136	Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. Brazilian Journal of Infectious Diseases, 2010, 14, 639-640.	0.3	1
137	First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national referral tuberculosis centre, Iran. International Journal of STD and AIDS, 2009, 20, 566-570.	0.5	9
138	Drug abuse profile – patient delay, diagnosis delay and drug resistance pattern – among addict patients with tuberculosis. International Journal of STD and AIDS, 2009, 20, 320-323.	0.5	12
139	Eight Years of Lung Transplantation: Experience of the National Research Institute of Tuberculosis and Lung Diseases. Transplantation Proceedings, 2009, 41, 2887-2889.	0.3	7
140	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. International Journal of Infectious Diseases, 2009, 13, e236-e240.	1.5	69
141	Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculosis Mycobacteria. American Journal of the Medical Sciences, 2009, 337, 182-184.	0.4	35
142	The Recent-Transmission of Mycobacterium tuberculosis Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping. BMC Infectious Diseases, 2008, 8, 109.	1.3	43
143	Pulmonary Aspergillosis in Solid Organ Transplant Patients: A Report From Iran. Transplantation Proceedings, 2008, 40, 3663-3667.	0.3	9
144	Impact of clinical pharmacistâ€led antibiotic stewardship program on clinical outcomes in a tertiary referral hospital. Journal of Pharmacy Practice and Research, 0, , .	0.5	0